Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Public ClinicalTrials.gov record NCT02178241. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Study identification
- NCT ID
- NCT02178241
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Enrollment
- 26 participants
Conditions and interventions
Conditions
- Metastatic Ureter Carcinoma
- Metastatic Urethral Carcinoma
- Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
- Stage III Ureter Cancer AJCC v7
- Stage III Urethral Cancer AJCC v7
- Stage IV Bladder Urothelial Carcinoma AJCC v7
- Stage IV Ureter Cancer AJCC v7
- Stage IV Urethral Cancer AJCC v7
- Ureter Urothelial Carcinoma
- Urethral Urothelial Carcinoma
Interventions
- Eribulin Mesylate Drug
- Gemcitabine Hydrochloride Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2014
- Primary completion
- Mar 17, 2019
- Completion
- Jul 10, 2019
- Last update posted
- Dec 15, 2019
2014 – 2019
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| Los Angeles County-USC Medical Center | Los Angeles | California | 90033 | — |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Keck Medical Center of USC Pasadena | Pasadena | California | 91105 | — |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | — |
| Moffitt Cancer Center P2C | Tampa | Florida | 33612 | — |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| UC Comprehensive Cancer Center at Silver Cross | New Lenox | Illinois | 60451 | — |
| Mayo Clinic Cancer Center P2C | Rochester | Minnesota | 55905 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Case Western Reserve University | Cleveland | Ohio | 44106 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania | 15232 | — |
| University of Texas M D Anderson Cancer Center P2C | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02178241, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 15, 2019 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02178241 live on ClinicalTrials.gov.